Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145
MALVERN, PA —Venatorx Pharmaceuticals announced positive top-line results for its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial (ClinicalTrials.gov – NCT04243863) of VNRX-7145, a novel …
Venatorx Pharmaceuticals Announces Positive Phase 1 Results for VNRX-7145 Read More